DermTech Inc

DermTech, Inc. engages in the development and sale of products for the diagnosis and treatment of skin diseases. It markets and develops products that facilitate diagnosis and management of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. Its products and services include melanoma test, smart sticker, and telemedicine option for melanoma test. The company was founded in 1995 and is headquartered in La Jolla, CA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

DermTech sees growth in test volumes despite revenue decline

DermTech's Q4 performance reflects growth in coverage and billable sample volumes, despite a decline in total revenue.
The company's strengths lie in expanding market acceptance, stabilized ASPs, and efforts to reduce payer friction.
Challenges include revenue diversification, leadership transition, and uncertainties in ASP trends, while opportunities exist in payer discussions and operational enhancements.

DermTech Inc reports revenue growth and volume increases in Q1

DermTech Inc's Q1 2023 performance showed revenue growth and volume increases, with a focus on stabilizing ASP and driving reimbursed volumes.
While facing challenges with flat DMT volumes and frustration over national payers' views, the company is optimistic about broader acceptance and cost-saving initiatives.
Opportunities lie in TRUST 2 study results influencing payer discussions, momentum with other payers, and targeting physicians with aligned payer mixes.

DermTech reports mixed Q2 results, focuses on revenue growth

DermTech faces challenges with flat DMT volumes and higher operating expenses but is leveraging strengths in insurance partnerships and revenue prioritization.
Opportunities lie in the growth potential of the DMT, expanding coverage, and optimizing sales strategies for revenue enhancement.
Overall, DermTech's financial performance in Q2 2023 reflects a strategic focus on revenue growth amidst operational challenges.

DermTech reports improved Q3 performance, eyes TRUST 2 study impact

DermTech's Q3 2023 performance showcased positive trends in ASP, revenue, and operational efficiency, despite a net loss.
Strategic strengths in sales team alignment, clinical value emphasis, and liquidity position the company well for future growth.
Challenges lie in maintaining test volumes, sustaining margins, and addressing cost reductions and effective payer communications.
Opportunities include TRUST 2 study results, legislative efforts, and focusing on reimbursed tests for revenue growth.

DermTech Inc reports robust Q4 growth and strategic cost reductions

DermTech Inc's Q4 2023 performance showcased strong growth in key metrics and financial health.
The company's focus on precision genomics and cost efficiencies positions it well for future success.
Challenges lie in sustaining revenue growth, optimizing expenses, and engaging payers effectively.
Opportunities abound in expanding reimbursed tests, revenue, and market presence for long-term growth.

The full company name is Design Media Technology, Inc.

SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its third-quarter 2023 financial results. “We're just a few months into our strategy of prioritizing reimbursed tests and growing revenue and are seeing faster progress than we expected,” said Bret Christensen, CEO, DermTech. “We significantly improved many of our key performance indicators in the third quarter.

DermTech Reports Third-Quarter 2023 Financial Results

NEW YORK , Oct. 27, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of DermTech, Inc. (NASDAQ: DMTK) between May 3, 2022 and November 3, 2022, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.

DMTK INVESTOR NEWS: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages DermTech, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DMTK

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of DermTech, Inc. (NASDAQ: DMTK) between May 3, 2022 and November 3, 2022, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 15, 2023. SO WHAT: If you purchased DermTech securities during the Class Period.

EQUITY ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages DermTech, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – DMTK

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming December 15, 2023 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased DermTech, Inc. (“DermTech” or the “Company”) (NASDAQ: DMTK) securities between May 3, 2022 and November 3, 2022, inclusive (the “Class Period”). Investors suffering losses on their DermTech investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal ri.

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against DermTech, Inc. (DMTK)

SAN DIEGO--(BUSINESS WIRE)---- $DMTK #DermTechInc--DermTech, Inc. (DMTK) Misled Investors Regarding its Business Prospects.

DermTech, Inc. (DMTK) Investor Notice: Robbins LLP Reminds Investors of Class Action Filed Against DermTech, Inc.

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming December 15, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired DermTech, Inc. (“DermTech” or the “Company”) (NASDAQ: DMTK) securities between May 3, 2022 and November 3, 2022, inclusive (the “Class Period”). If you suffered a loss on your DermTech investments or would like to inquire about potentially pursuing cl.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against DermTech, Inc. (DMTK)

NEW YORK--(BUSINESS WIRE)---- $DMTK #classactionlawsuit--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of California on behalf of those who acquired DermTech, Inc. (“DermTech” or the “Company”) (NASDAQ: DMTK) securities during the period from May 3, 2022 through November 3, 2022, inclusive (the “Class Period”). Investors have until December 15, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit. On August.

Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of DermTech, Inc. (DMTK) Investors

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning DermTech business and prospects, resulting in its stock trading at inflated prices.

DMTK INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that DermTech, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against DermTech, Inc. (“DermTech” or the “Company”) (NASDAQ: DMTK) in the United States District Court for the Southern District of California on behalf of all persons and entities who purchased or otherwise acquired DermTech securities between May 3, 2022 and November 3, 2022, both dates inclusive (the “Class Period”). Investors.

DERMTECH ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against DermTech, Inc. and Encourages Investors to Contact the Firm

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased DermTech, Inc. (“DermTech” or the “Company”) (NASDAQ: DMTK) securities between May 3, 2022 and November 3, 2022, inclusive (the “Class Period”). DermTech investors have until December 15, 2023 to file a lead plaintiff motion. Investors suffering losses on their DermTech investments are encouraged to contact the Law Offices of Howard G. Smith to.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of DermTech, Inc. (DMTK) Investors

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), announces that it has filed a class action lawsuit in the United States District Court for the Southern District of California, captioned Bagheri v. DermTech, Inc., et al., on behalf of persons and entities that purchased or otherwise acquired DermTech, Inc. (“DermTech” or the “Company”) (NASDAQ: DMTK) securities between May 3, 2022 and November 3, 2022, inclusive (the “Class Period”). Plaintiff pursues claims under Sections.

DMTK CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against DermTech, Inc.

SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, will host a conference call and webcast on Thursday, November 2, 2023 at 5:00 p.m. Eastern Time (ET) to discuss the Company's third-quarter 2023 operating and financial results. In advance of the call on November 2, 2023, DermTech will issue its third-quarter 2023 earnings press release. For participants interested in asking q.

DermTech Announces Release Date for Third-Quarter 2023 Financial Results

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of DermTech, Inc. (“DermTech” or the “Company”) (NASDAQ: DMTK) investors concerning the Company's possible violations of federal securities laws. On August 8, 2022, DermTech disclosed that it was reducing its full-year 2022 outlook to reflect a lower average selling price (ASP) for the Company's DermTech Melanoma Test (DMT). The Company claimed that “[t]he ASP pressure is primarily the result of.

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of DermTech, Inc. (DMTK) on Behalf of Investors

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against DermTech, Inc. (“DermTech” or the “Company”) (NASDAQ: DMTK) on behalf of DermTech stockholders. Our investigation concerns whether DermTech has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. The investigation by a law firm concerns whether certain DermTech dir.

DERMTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating DermTech, Inc. on Behalf of DermTech Stockholders and Encourages Investors to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of DermTech, Inc. (“DermTech” or the “Company”) (NASDAQ: DMTK) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your DermTech investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your conta.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of DermTech, Inc. (DMTK) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of DermTech, Inc. (“DermTech” or the “Company”) (NASDAQ: DMTK) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On August 8, 2022, DermTech disclosed that it was reducing its full-year 2022 outlook to reflect a lower average selling price (ASP) for the Company's DermTech Melanoma Test (D.

The Law Offices of Frank R. Cruz Continues Investigation of DermTech, Inc. (DMTK) on Behalf of Investors

SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that DermTech's Compensation Committee has granted an equity award to its new chief commercial officer, Mark Aguillard. The award was granted pursuant to the terms of Mr. Aguillard's employment letter and as a material inducement to his joining the Company as chief commercial officer. On September 20, 2023, Der.

DermTech Grants New CCO Mark Aguillard Inducement Award Under NASDAQ Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced agreements with Highmark Inc. (Highmark). The contracts, which are in addition to a favorable coverage policy, enhance access to the foundational assay of the DermTech Melanoma Test (DMT). Highmark and its Blue-branded affiliates provide health insurance to approximately 7 million members in Pennsylvania, West.

DermTech Announces Contracts With Highmark for the Foundational Assay of Its DermTech Melanoma Test (DMT)

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of DermTech, Inc. (“DermTech” or the “Company”) (NASDAQ: DMTK) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your DermTech investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of DermTech, Inc. (DMTK) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of DermTech, Inc. (“DermTech” or the “Company”) (NASDAQ: DMTK) investors concerning the Company's possible violations of federal securities laws. On August 8, 2022, DermTech disclosed that it was reducing its full-year 2022 outlook to reflect a lower average selling price (ASP) for the Company's DermTech Melanoma Test (DMT). The Company claimed that “[t]he ASP pressure is primarily the result of.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of DermTech, Inc. (DMTK) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of DermTech, Inc. (“DermTech” or the “Company”) (NASDAQ: DMTK) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On August 8, 2022, DermTech disclosed that it was reducing its full-year 2022 outlook to reflect a lower average selling price (ASP) for the Company's DermTech Melanoma Test (DM.

The Law Offices of Frank R. Cruz Announces Investigation of DermTech, Inc. (DMTK) on Behalf of Investors

SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the appointment of Mark Aguillard as chief commercial officer effective September 19, 2023. Mr. Aguillard will lead DermTech's overall commercial strategy and execution. Commenting on Mr. Aguillard's appointment, Bret Christensen, DermTech's CEO said, “I'd like to welcome Mark to the team. We are confident that.

DermTech Appoints Mark Aguillard as Chief Commercial Officer

DermTech, Inc. (NASDAQ:DMTK ) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Company Participants Steve Kunszabo - Head, Investor Relations Bret Christensen - President & Chief Executive Officer Kevin Sun - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Operator Good day, and thank you for standing by. Welcome to DermTech's Second Quarter 2023 Financial Results Call.

DermTech, Inc. (DMTK) Q2 2023 Earnings Call Transcript

DermTech, Inc. (DMTK) came out with a quarterly loss of $0.99 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to loss of $0.99 per share a year ago.

DermTech, Inc. (DMTK) Reports Q2 Loss, Tops Revenue Estimates

SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its second-quarter 2023 financial results. “We've recently taken a few necessary steps to streamline operations and put all our energy into scaling the DermTech Melanoma Test (DMT) and prioritizing reimbursed billable samples to grow revenue,” said Bret Christensen, CEO, DermTech. “We're pursuing a large address.

News for DermTech Inc Stock (DMTK)